Similarly, patients with TP53a from the CLL-14 trial had a shorter PFS (2-year PFS around 70%) than those with intact TP53. A slightly higher 2-year PFS (75–80%) has been reported on ibrutinib trials what has led some experts to recommend ibrutinib over venetoclax in TP53a [2,10]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.